INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ZoomInfo Technologies Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP filed a securities class action against ZoomInfo, alleging possible securities fraud/unlawful business practices. The filing references ZoomInfo’s May 11 Q1 2026 results that cut 2026 full-year guidance after a sharp decline in its growth outlook, which coincided with the stock dropping $1.98 (32.78%) to $4.06 on May 12, 2026.

Analysis

This is better thought of as an overhang on already-damaged credibility than a new fundamental event. In software names like GTM, class actions rarely move intrinsic value unless they uncover a disclosure-control problem; the real market mechanism is that litigation keeps long-only capital sidelined and makes the prior guidance reset feel less like a one-off. The immediate beneficiary is the plaintiffs’ bar; the more durable winners are adjacent B2B software platforms with cleaner execution records and broader budgets, where sales teams can reallocate spend without reputational friction.

The next 1-3 months matter more than the lawsuit timeline itself. If management’s next update shows another step-down in bookings or retention, the case becomes a convenient narrative anchor for a second de-rating leg; if the company stabilizes metrics, the legal process should fade into background noise. The tail risk is a follow-on SEC inquiry or restatement, which would convert this from a nuisance into a governance issue and likely force a bigger multiple compression than the current selloff implies.

My base case is that the market is still underweighting the possibility of further fundamental disappointment and overweighting the lawsuit headline. The contrarian view is that the stock may already be close to where litigation risk is no longer the main variable; if so, fresh shorts here are lower quality than shorts taken on any relief rally. What would falsify the bearish view is two consecutive quarters of stabilized ARR/bookings plus no secondary disclosure action; absent that, this remains a low-conviction name to own.

Key Decisions for Investors

• Do not add fresh long GTM exposure for 1-2 weeks; the lawsuit is not the thesis, but it preserves a valuation discount until the next operating update proves stabilization.
• If GTM rallies 8-12% on headline fatigue, use the bounce to initiate a 1-3 month short or buy a defined-risk 3-6 month put spread; the pay-off is another guide reset rather than legal damages.
• Pair trade: long CRM or HUBS vs short GTM over 1-3 months to express a quality-vs-execution spread in B2B software; this isolates the read-through to cleaner recurring-revenue names.
• Set an alert for the August 25 lead-plaintiff deadline and the next earnings call; cover/trim bearish exposure if management reaffirms guidance and there is no SEC follow-on or restatement risk.